{"groups":[{"description":"Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, liposomal cytarabine, methotrexate: Weeks 1-15:\n\n* 6 cycles of CHOP on Days 1 to 5, to be repeated q21 Days\n* Rituximab 375 mg/m2 on Day 0 or Day 1 of every CHOP cycle\n* IT chemoth:Depocyte 50 mg on Day 0 of cycles 2,3,4\\&5 of R-CHOP\n\nWeeks 18-22:\n\n• Methotrexate 1.5 g/m2 q14 Days x 2\n\nFrom Week 24:\n\n• Scrotal prophylactic radiotherapy or involved field radiotherapy(but can be planned concomitantly to R-CHOP in pts with bilateral disease)","id":"FG000","title":"R-CHOP, Depocyte, Methotrexate"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Second malignancy"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"54"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"45"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"9"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Recruitment lasted from 27 September 2009 to 13 July 2017"}